Company: STAA
Filing Date: 2025-10-06
Form Type: DEFA14A
Source: 0001193125-25-230935
Chunk: 0

Company: STAAR SURGICAL CO
Filing Date: 2025-10-06
Form: DEFA14A
Chunk 0
---
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box:

| ☐ | Preliminary Proxy Statement |

| ☐ | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |

| ☐ | Definitive Proxy Statement |

| ☒ | Definitive Additional Materials |

| ☐ | Soliciting Material under § 240.14a-12 |

STAAR SURGICAL COMPANY (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box):

| ☒ | No fee required. |

| ☐ | Fee paid previously with preliminary materials. |

| ☐ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11. |

On October 6, 2025, STAAR Surgical Company (“STAAR”) issued the following press release:

STAAR Surgical Addresses Broadwood Partners’ Flawed, Misleading, and Misinformed Claims

Alcon Merger Represents 59% Premium to the 90-DayVWAP Prior to the Announcement

The STAAR Board of Directors Strongly Encourages ALL Stockholders to Vote “FOR” the Alcon Merger on the WHITE Proxy Card

LAKE FOREST, CA, October6, 2025 –STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the
EVO family of Implantable Collamer Lenses (EVO ICL) for vision correction, today issued the following statement with respect to the
flawed, misleading, and misinformed claims recently made by Broadwood Partners, L.P.:

Broadwood’s recent presentation recycles flawed, misleading,
and misinformed claims about the process and considerations leading up to STAAR’s agreement with Alcon and the certain, compelling, premium cash value this transaction provides. Broadwood’s claims have been refuted in detail in
STAAR’s investor materials, including in its “STAAR Surgical Publishes Presentation Highlighting Compelling,